CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 193,099 enrolled
Drug / intervention
Pioglitazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01637935
NCT01637935N/ACompleted
CompareCT.gov

Cohort Study of Pioglitazone and Bladder Cancer in Patients With Diabetes

Takeda·observational·Posted Jul 11, 2012·Updated Mar 7, 2018

In Brief

An observational study evaluating Pioglitazone for Diabetes and Bladder Cancer. Completed, enrolled 193,099 participants.

Detailed Summary

To assess the potential association between pioglitazone and bladder cancer compared with non-pioglitazone users among patients with type 2 diabetes mellitus.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Bladder Cancer
Countries--
CollaboratorsKaiser Permanente, Department of Epidemiology at University of Pennsylvania

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 11, 2012
Enrollment StartJul 1, 2004
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 10.1 yearsPosted 14.0 years ago

Interventions

Pioglitazonedrug

Pioglitazone tablets.